Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Morandi

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Leukemia & Lymphoma|December 17, 2002
Harvesting of autologous blood stem cells after a mobilising regimen with low-dose cyclophosphamideGiorgio Lambertenghi Deliliers, Claudio Annaloro, Maurizio Marconi, et al.
International Journal of Molecular Sciences|November 6, 2015
Notch Cooperates with Survivin to Maintain Stemness and to Stimulate Proliferation in Human Keratinocytes during AgeingElisabetta Palazzo, Paolo Morandi, Roberta Lotti, et al.
Risk Management and Healthcare Policy|May 26, 2022
Use of Routine Health Datasets to Assess the Appropriateness of Diagnostic Tests in the Follow-Up of Breast Cancer Patients: A Population-Based Study on 3930 PatientsMassimo Gion, Giulia Cardinali, Stefano Guzzinati, et al.
International Journal of Molecular Sciences|October 1, 2013
Isolation and characterization of squamous cell carcinoma-derived stem-like cells: role in tumor formationKatiuscia Dallaglio, Tiziana Petrachi, Alessandra Marconi, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2018
Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY studyMilvia Zambetti, Filippo Montemurro, Paolo Morandi, et al.
Frontiers in Immunology|February 7, 2024
Real-world impact of the introduction of chemo-immunotherapy in extended small cell lung cancer: a multicentric analysisLaura Bonanno, Lorenzo Calvetti, Alessandro Dal Maso, et al.
Breast Cancer Research and Treatment|July 14, 2011
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II)Milvia Zambetti, Mauro Mansutti, Patricia Gomez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
Breast cancer molecular subtypes respond differently to preoperative chemotherapyRoman Rouzier, Charles M Perou, W Fraser Symmans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapyAna M Gonzalez-Angulo, Sean E McGuire, Thomas A Buchholz, et al.
The Oncologist|June 2, 2019
Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE StudyMaria Vittoria Dieci, Valentina Guarneri, Fable Zustovich, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Leukemia & Lymphoma|December 17, 2002
Harvesting of autologous blood stem cells after a mobilising regimen with low-dose cyclophosphamideGiorgio Lambertenghi Deliliers, Claudio Annaloro, Maurizio Marconi, et al.
International Journal of Molecular Sciences|November 6, 2015
Notch Cooperates with Survivin to Maintain Stemness and to Stimulate Proliferation in Human Keratinocytes during AgeingElisabetta Palazzo, Paolo Morandi, Roberta Lotti, et al.
Risk Management and Healthcare Policy|May 26, 2022
Use of Routine Health Datasets to Assess the Appropriateness of Diagnostic Tests in the Follow-Up of Breast Cancer Patients: A Population-Based Study on 3930 PatientsMassimo Gion, Giulia Cardinali, Stefano Guzzinati, et al.
International Journal of Molecular Sciences|October 1, 2013
Isolation and characterization of squamous cell carcinoma-derived stem-like cells: role in tumor formationKatiuscia Dallaglio, Tiziana Petrachi, Alessandra Marconi, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2018
Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY studyMilvia Zambetti, Filippo Montemurro, Paolo Morandi, et al.
Frontiers in Immunology|February 7, 2024
Real-world impact of the introduction of chemo-immunotherapy in extended small cell lung cancer: a multicentric analysisLaura Bonanno, Lorenzo Calvetti, Alessandro Dal Maso, et al.
Breast Cancer Research and Treatment|July 14, 2011
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II)Milvia Zambetti, Mauro Mansutti, Patricia Gomez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
Breast cancer molecular subtypes respond differently to preoperative chemotherapyRoman Rouzier, Charles M Perou, W Fraser Symmans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapyAna M Gonzalez-Angulo, Sean E McGuire, Thomas A Buchholz, et al.
The Oncologist|June 2, 2019
Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE StudyMaria Vittoria Dieci, Valentina Guarneri, Fable Zustovich, et al.
Pageof 3